



Professional address:

Centre Hospitalier
Universitaire Brugmann
Van Gehuchten Plein 4
1020 Laken, Brussels
Belgium
Phone: +32 (0)2 477 27 26
Mobile: +32(0)486 20 56 72
anne.rogiers@chubrugmann.be
INAMI: 1-08811-23-780

Personal address:

Rozenlaan 9
1730 Asse (Mollem)
België
Tel.: + 32 (0)2 452 21 79

Anne Rogiers, MD Psychiatrist

Personal data

- Nationality: Belgium
- Place of birth: Bruges, Belgium
- Date of birth: 05/05/1967

Education

- 2017: Thérapie brève du trauma, TBT
- 2017: Cognitive Remediation Therapy, CRT
- 2016: Formation de Rémediation Cognitive, RECOS
- 2001: Specialization as a psychiatrist
- 1996: Licence complémentaire : Cliniques Psychothérapeutiques, Adultes, Université Libre de Bruxelles (ULB)
- 1994: Medical Doctor, Free University Brussels (VUB Brussels)
- 1987: Bachelor in Psychology, Free University of Brussels (VUB)
- 1985: High school: Science-mathematics, Koninklijk Atheneum III, Brugge

Ongoing Research

- Psycho-social outcome and neurocognitive function in survivors of advanced melanoma treated with immune checkpoint inhibitor therapy (ICIT) , Study sponsor UZ Brussel, Principal Investigator: B. Neyns, Investigator: A. Rogiers
- Late physical, psychological and social consequences of ipilimumab treatment in advanced melanoma: A multicenter cohort study” , Study sponsor: Antoni Van Leeuwenhoek ziekenhuis, Amsterdam, Study director: Micheal Lees, Investigators for UZ Brussel: B. Neyns, A. Rogiers
- Phase II clinical trial on the combination of avelumab and axitinib for the treatment of patients with recurrent glioblastoma, Study sponsor UZ Brussel, 2017BN-001, Principal investigator: B. Neyns, Investigator: A. Rogiers for QoL and Neurocognitive function

Professional memberships

- Vlaamse vereniging voor psychiatrie (VVP)
- Association Francophone de Remédiation Cognitive (AFRC)
- American Society of Clinical Oncology (ASCO)
- Member of the EORTC quality of life Group
- Member of the EORTC Melanoma group

Awards

- Award for Scientific Research in Psychiatry, Brugmann Foundation: "Understand and identify the possible neurocognitive and emotional problems in melanoma survivors treated with immunotherapy in order to develop detection tools and offer adapted care"

Peer reviewed publications

- "Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors" Anne Rogiers, Annelies Boekhout, Julia K. Schwarze, Gil Awada, Christian U. Blank, Bart Neyns, Journal of Oncology, vol. 2019, Article ID 5269062, 17 pages, 2019. <https://doi.org/10.1155/2019/5269062>.
- "Implementation intention for initiating intuitive eating and active embodiment in obese patients using a smartphone application" D. Brevers, A. Rogiers, A. Defontaine, G. Cheron, A. Clarinval, J. Foucart, A. Bouchez, V. Bolly, L. Tsartsafloudakis, P. Jottrand, P. Minner, A. Bechara, C. Kornreich, P. Verbanck, Front Psychiatry. 2017 Nov 21;8: 243
- "Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma" J. Duerinck, S. Du Four, F. Bouttens, Andre C, V. Verschaeve, F. Van Fraeyenhove, C. Chaskis, N. D'Haene, M. Le Mercier, A. Rogiers, I. Salmon, B. Neyns, J Neurooncol. 2018 Jan; 136(1):115-125
- "Patient outcome in the Belgian Medical Need Program on bevacizumab for recurrent glioblastoma" J. Duerinck, P. Clement, F. Bouttens, C. Andre, B. Neyns, Y. Staelens, F. Van Fraeyenhove, J.F. Baurrain, S. Luce, L. D'hondt, E. Joossens, P. Specenier, V. Verschaeve, B. Filleul, P. Vroman, B. Stragier, A. Rogiers, J Neurol. 2015 Mar;262(3):742-51.
- "The role of cytotoxic drugs in the treatment of central nervous system glioma's" M. d'haeseleer, J. Van de Cauter, A. Rogiers, A. Michotte, B. Neyns, H. Strik, Acta Neurologica Belgica 2010,110,1-14
- "Correlates of unrecognized depression among hospitalized geriatric patients." Pepersack T, De Breucker S, Mekongo YP, Rogiers A, Beyer I., J Psychiatr Pract. 2006 May; 12(3):160-7

Oral Presentations and poster presentations at international conferences

- “Emotional and cognitive disturbances in long-term melanoma survivors treated with ipilimumab” A. Rogiers, J. De Cremer, L. Ben Salama, J. Swarze, G. Awada, P. Theuns, B Neyns, Poster at ASCO SITC, San Fransisco, 2019,) *Journal of Clinical Oncology, vol. 37, Supplement 8, Abstract 97, 2019.*
- “Emtional disturbances, Quality of life, neuro-cognitive function and psychosocial outcome in advanced melanoma survivors treated with pembrolizumab” A. Rogiers, J. De Cremer, L. Ben Salama, J. Swarze, G. Awada, P. Theuns, M. De Ridder, B. Neyns , oral presentation at the Immuno Bridge Napels, *J of Translational Research, supplement,2019*
- “Psychosocial outcome and health-related Quality of life (HRQoL) in advanced melanoma survivors”, A. Rogiers, J. De Cremer, L. Ben Salama, M. De Ridder, J.L. Bernheim, B. Neyns, P. Theuns, presented as a poster at the ASCO Cancer Survivorship Symposium, 2018, *Journal of Clinical Oncology, supplement 8, 2018*
- “Psychosocial outcome, neurocognitive functioning (NCF) and quality of life in advanced melanoma survivors” A. Rogiers, J. De Cremer, L. Ben Salama, Y. Janssen, J.L. Berheim, P. Theuns, B. Neyns, presented as a poster at Society for Melanoma Research, Brisbane, Australia, 2017
- “Bevacizumab for Recurrent Glioblastoma : Observations of Patient Outcome in the Belgian Medical Need Program” J. Duerinck, P. Clement, F. Bouttens, B. Neyns, L. Dhondt, C. Gennigens, F. Van Fraeyenhove, E. Joosens, S. Luce, Y. Staelens, J.F. Baurain, P. Specenier, V. Verschaeve, P. Vroman, B. Filleul, A. Rogiers. Presented as a poster at EANO (European Association of Neuro-oncology), 10th congress in Marseille, 2012
- “Fatal adverse drug reactions with antipsychotics as suspected drug”, A. Rogiers, A. Van Ermen, T. Roisin, oral presentation at the 6th Annual Meeting of the International Society of Pharmacovigilance, Luik, 2006 (ISOP)
- “Cardiac adverse effects with cholinesterase inhibitors”, T. Roisin, A. Van Ermen, A. Rogiers, presented as a poster at the 6th Annual Meeting of the International Society of Pharmacovigilance, Luik, 2006 (ISOP)
- “Clinical trials: diagnostic tools” oral presentation at the CNS assessors meeting of the European College of Neuropsychopharmacology (ECNP), Nice 2003
- “Antipsychotics: distinction between antipsychotic, anti-aggressive and sedative effect of antipsychotics in the treatment of dementia” oral presentation at the CNS assessors meeting of the European College of Neuropsychopharmacology (ECNP), Nice 2002
- “The prevalence of unrecognized depression in geriatric medical inpatients” A. Rogiers, D. Lecompte, T. Pepersack, P. Rotsaert, F. Benoit, presented as a poster at International Psychogeriatric Congress, Nice (2001)
- “The use of specific assessment tools can prevent the underestimation of depression in geriatric inpatients” A. Rogiers, D. Lecompte, T. Pepersack, A. Mergam, I. Beyer, J. Snacken, presented as a poster at the International Psychogeriatric Congress Nice (2001)

